Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

sands) Three MonthsEnded September 30,Nine MonthsEnded September 30,2013201220132012Revenues

$

7,678$

4,282$

25,817$

14,689Operating expenses:Research and development

4,4848,16920,15330,120General and administrative

3,0761,2307,0494,533Gain on sale of kinase profiling services business

(2,500)(480)(2,500)(1,600)Total operating expenses

5,0608,91924,70233,053Income (loss) from operations

2,618(4,637)1,115(18,364)Other expenses, net

(8,687)(2,028)(10,326)(3,604)Consolidated net loss

$

(6,069)$

(6,665)$

(9,211)$

(21,968) Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Balance Sheets(in thousands) September 30,2013December 31,2012(unaudited)Cash and cash equivalents$

78,856$

17,481Other assets1,0941,948Property and equipment, net816560Total assets$

80,766$

19,989Accounts payable, accrued expenses and other liabilities

$

6,397$

12,923Deferred revenue—20,671Warrant liabilities15,62310,540Redeemable non-controlling interest—3,323Convertible preferred stock—170,778Stockholders' equity (deficit)58,746(198,246)Total liabilities and stockholders' equity$

80,766$

19,989 Ambit Contacts: Marcy Graham

Andrew McDonald, Ph.D.Executive Director, Investor Relations & Corp CommLifeSci Advisors, LLCAmbit Biosciences, Inc.

Founding Partner858-334-2125

646-597-6987mgraham@ambitbio.com

andrew@lifesciadvisors.com 


'/>"/>
SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... and BANGALORE, India , ... genomic profiling company that uses next generation sequencing technology ... Scott A. Storrer as chief executive officer. ... he will be responsible for all strategy, business expansion ... , who has served as Strand,s chairman and CEO ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences ... focused on the treatment of dementia, today announced ... on July 22 at 5:45 p.m. EDT following ... Alzheimer,s Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , ...
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... Feb. 1 Fears that the economy is not,only ... had,investors in a skittish mood during January. However, biotech ... well ahead of the,NASDAQ, which posted a January loss ... "Healthcare is usually able to ride out extremely volatile ...
... 1 Taligen Therapeutics, Inc. today,announced it anticipates ... Series B,financing. The financing was led by Alta ... including Sanderling Ventures, Tango,and High Country Venture., ... infusion of capital but the,addition of two world ...
... DIEGO, Feb. 1 Cardium Therapeutics (Amex:,CXM) ... million registered direct,offering with institutional and other ... on January 31, 2008. Empire Asset Management,Company ... the transaction., (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ), ...
Cached Biology Technology:January Market Jitters Fails to Derail Biotech 2January Market Jitters Fails to Derail Biotech 3January Market Jitters Fails to Derail Biotech 4Taligen Therapeutics Secures Series B Financing 2Cardium Completes $5.3 Million Registered Direct Offering 2Cardium Completes $5.3 Million Registered Direct Offering 3Cardium Completes $5.3 Million Registered Direct Offering 4
(Date:6/17/2015)... Deutschland und GERMANTOWN, Maryland , June ... ®   Produktlinie mit DNA-Tests verbessert den ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) hat ... STR-Testkits der Produktlinie Investigator ® ... Markt eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards has received ... in the company,s portfolio from one of its module partners ... mainly take place during the third quarter 2015. The sensors ... . Jörgen Lantto, CEO of FPC, comments: ...   growing interest from smartphone OEMs in integrating touch fingerprint ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... in Colombia,s Cerrejn coal mine by researchers from the Smithsonian ... Natural History helps to explain the origin of one of ... Cerrejonemys wayuunaiki takes its genus name from Cerrejn, ... spoken by the Wayuu people who live on the Guajira ...
... if you are making cellulosic ethanol, you want less lignin ... are using pyrolytic methods, you want more lignin because lignin ... or minimize lignin content, an understanding of lignin synthesis is ... adaptation to life on land, as it strengthens plant cell ...
... through which it can protect itself against newly-developing cancer ... in our organs every day. Once tumours have developed, ... from the immune system. Scientists from the research group ... (HZI) in Braunschweig have now succeeded to reveal a ...
Cached Biology News:Convergent evolution in lignin biosynthesis: Tools for re-engineering biomass composition 2The immune system's guard against cancer 2The immune system's guard against cancer 3